Business Standard

Dr Reddy's SEZ unit completes USFDA inspection for second time

US drug regulator audited company's API manufacturing unit at the same plant in April

reddy, dr reddy's
Premium

Dr Reddy's laboratory

BS Reporter Hyderabad
Hyderabad-based Dr Reddy's Laboratories informed the stock exchanges that the US Food and Drug Administration (USFDA) has completed the audit of its formulations at unit II in Srikakulum's special economic zone (SEZ) in Andhra Pradesh on Thursday.
According to the compnay, the USFDA has made no observations after the inspection. 
In April, the US drug regulator had inspected Dr Reddy's active pharmaceutical ingredients (APIs) manufacturing unit at the same SEZ plant in Srikakulam with no observations. After the inspection of yet another API facility at Srikakulam in the month of April, the USFDA had issued Form 483 after making two observations.
The USFDA

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in